Ado-Trastuzumab Emtansine
(A-doh-tras-TOO-zoo-mab em-TAN-seen) This page contains brief information about ado-trastuzumab emtansine and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
| US Brand Name(s): |  | Kadcyla |
| | ||
| | ||
| FDA Approved: | | Yes |
FDA Approval for Ado-Trastuzumab Emtansine
Use in CancerAdo-trastuzumab emtansine is approved to treat:
- Breast cancer that is HER2 positive and has metastasized (spread to other parts of the body). It is used in patients who have already been treated with trastuzumab and a taxane. It is also used in these patients if the cancer recurs (comes back) after adjuvant therapy.
Ado-trastuzumab emtansine is also being studied in the treatment of other types of cancer.
More About Ado-Trastuzumab EmtansineDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research ResultsFor Some Breast Cancers, New Drug May Be Treatment Option - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trials Accepting PatientsFind Clinical Trials for Ado-trastuzumab Emtansine - Check for trials from NCI's list of cancer clinical trials now accepting patients.
Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top